Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial（iFORCE）

NCT05465343 is registered in ClinicalTrials.gov with Peking Union Medical College as lead sponsor.

NCT NCT05465343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05465343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial（iFORCE）
Lead sponsor
Peking Union Medical College
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2022
Completion date
December 12, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, egfr-mutation, furmonertinib, nsclc